RT Journal Article
SR Electronic
T1 The time scale of asymptomatic transmission affects estimates of epidemic potential in the COVID-19 outbreak
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.09.20033514
DO 10.1101/2020.03.09.20033514
A1 Sang Woo Park
A1 Daniel M. Cornforth
A1 Jonathan Dushoff
A1 Joshua S. Weitz
YR 2020
UL http://medrxiv.org/content/early/2020/04/14/2020.03.09.20033514.abstract
AB The role of asymptomatic carriers in transmission poses challenges for control of the COVID-19 pandemic. Study of asymptomatic transmission and implications for surveillance and disease burden are ongoing, but there has been little study of the implications of asymp- tomatic transmission on dynamics of disease. We use a mathematical framework to evaluate expected effects of asymptomatic transmission on the basic reproduction number ℛ0 (i.e., the expected number of secondary cases generated by an average primary case in a fully sus- ceptible population) and the fraction of new secondary cases attributable to asymptomatic individuals. If the generation-interval distribution of asymptomatic transmission differs from that of symptomatic transmission, then estimates of the basic reproduction number which do not explicitly account for asymptomatic cases may be systematically biased. Specifically, if asymptomatic cases have a shorter generation interval than symptomatic cases, ℛ0 will be over-estimated, and if they have a longer generation interval, ℛ0 will be under-estimated. Estimates of the realized proportion of asymptomatic transmission during the exponential phase also depend on asymptomatic generation intervals. Our analysis shows that understanding the temporal course of asymptomatic transmission can be important for assessing the importance of this route of transmission, and for disease dynamics. This provides an additional motivation for investigating both the importance and relative duration of asymptomatic transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch effort by JSW was enabled by support from grants from the Simons Foundation (SCOPE Award ID 329108), the Army Research Office (W911NF1910384), National Institutes of Health (1R01AI46592-01), and National Science Foundation (1806606 and 1829636). JD was supported, in part, by grants from the Canadian Institutes of Health Research.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code is available at https://github.com/mac-theobio/coronavirus_asymptomatic. https://github.com/mac-theobio/coronavirus_asymptomatic.